CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN CTO Registry Coronary Artery Calcium Is Associated with Left Ventricular Diastolic Function Independent of Myocardial Ischemia Incidence, Predictors, and Outcomes of In-Hospital Percutaneous Coronary Intervention Following Coronary Artery Bypass Grafting Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology

Guideline2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL:J Am Coll Cardiol. Article Link

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF